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Background/aim: Ticagrelor is a drug widely used in patients with acute coronary syndromes (ACS) that specifically increases
the plasma level of adenosine, which is likely to cause atrial fibrillation (AF). Therefore, in this study we aimed to investigate the
electrocardiographic and echocardiographic predictors of AF development after P2Y12 receptor antagonists in ACS patients.
Materials and methods: This cross-sectional study included 831 patients with ACS (486 [58.5%] with ST elevated myocardial infarction
[STEMI] and 345 [41.5%] with non-ST elevated myocardial infarction [NSTEMI]). Patients were divided into ticagrelor (n = 410) and
clopidogrel (n = 421) groups. P wave properties including P wave dispersion and atrial electromechanical conduction properties were
measured as AF predictors with surface ECG and tissue Doppler imaging.
Results: Baseline characteristics such as age, sex, heart rate, blood pressure, and laboratory parameters were almost the same in the
ticagrelor and clopidogrel groups. The statistical analysis showed no significant difference in P wave dispersion (PWD) between
ticagrelor and clopidogrel groups (40.98 ± 12 ms versus 40.06 ± 12 ms, P = 0.304). Subgroups analysis according to ACS types also
showed no significant difference in PWD (NSTEMI: 41.16 ± 13.8 ms versus 40.76 ± 13.55 ms, P = 0.799; STEMI: 40.9 ± 12.62 ms versus
39.19 ± 11.18 ms, P = 0.132). In addition, we did not find significant difference in atrial electromechanical delay (EMD) with tissue
Doppler imaging (interatrial EMD 24.11 ± 3.06 ms versus 24.46 ± 3.23 ms, P = 0.279).
Conclusion: In conclusion, we did not find any difference in detailed electrocardiographic and echocardiographic parameters as AF
predictors between ticagrelor and clopidogrel groups in patients with ACS.
Key words: Acute coronary syndrome, atrial fibrillation, ticagrelor

1. Introduction
Acute coronary syndromes (ACS) are one of the major
causes of mortality and morbidity worldwide. Current
guidelines recommend dual antiplatelet therapy in
patients with ACS [1,2]. Ticagrelor, one of the relatively
new drugs used in ACS, is a reversible and direct-acting
oral antagonist of adenosine diphosphate receptor P2Y12,
and it was found superior over clopidogrel in the PLATO
trial [3]. Although the benefit of ticagrelor has been
attributed mostly to its faster, greater, and more consistent
P2Y12 inhibition compared to clopidogrel, continuity of
growing benefits of ticagrelor and its effect on reduction
of cardiovascular mortality in the PLATO trial make it
different from other P2Y12-ADP receptor blockers [3–5].
These differences led to the hypothesis that ticagrelor

has pleiotropic properties and nonplatelet directed
mechanisms of action. These effects of ticagrelor have
been mostly attributed to increased half-life and plasma
concentration of adenosine [6,7].
Adenosine is a purine nucleoside primarily produced
by endothelial cells [8] and it has a number of effects,
such as coronary vasodilatation [9], inhibition of platelet
aggregation [10], modulation of inflammation [11],
reduced ischemia/reperfusion injury [12,13], and reduced
atrioventricular conduction [14]. Besides some positive
effects, it is also known that adenosine has the potential
to cause atrial fibrillation (AF) [15–17]. In addition,
there is a case report in the literature suggesting that
ticagrelor could cause AF, a possible mechanism of which
is increased plasma adenosine level [18]. However, there
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are no studies in the literature investigating the risk of AF
in patients treated with ticagrelor. In this study, we aimed
to determine whether ticagrelor predisposes to AF in ACS
patients by using surrogate electro and echocardiographic
parameters.
2. Materials and methods
This cross-sectional study was conducted between January
2016 and February 2017 on patients diagnosed with
ACS, which consists of ST elevated myocardial infarction
(STEMI) and non-ST elevated myocardial infarction
(NSTEMI). STEMI is defined as having a typical angina
that lasts 20 min or longer and with STEMI criteria in
ECG [2]. Non-ST-elevation myocardial infarction is
defined as a rise in troponin level (troponin-I > 0.06 ng/
mL) with typical chest pain without STEMI criteria in
ECG [1]. The treatment of the patients was arranged in
line with the European Society of Cardiology guidelines.
Patients were given 180 mg ticagrelor as the loading dose
in the ticagrelor group. Angiotensin converting enzyme
inhibitors, beta blockers, and statins were started in all
patients without contraindication within the first 24 h
after diagnosis. Patients were treated with percutaneous
coronary intervention (stent implantation or balloon
angioplasty). Patients who needed coronary bypass
surgery were not included in the study. The other exclusion
criteria were as follows: atrial infarction diagnostic
criteria described by Liu et al. [19], a history of AF, use
of antiarrhythmic drug other than beta-blockers, renal
dysfunction (creatinine >1.5 mg/dL), severe valvular heart
disease, permanent pacemaker, cerebrovascular disease,
and the need for mechanical ventilation. The study was
conducted following the principles of the Declaration
of Helsinki for Human Research and approved by the
institutional ethics committee.
Electro-echocardiographic evaluation was performed
on patients who had been treated for a median of 2.5
days. A 12-lead surface ECG was obtained from all study
participants nearly 2 h after the last dose of the clopidogrel/
ticagrelor in the supine position before discharge and
analyses were done with this ECG [20]. The point at which
the first atrial deflection crossed the isoelectric line was
defined as the beginning of the P wave and the return to
baseline was considered as the end of the P wave. Pmax
and Pmin durations were measured for all patients in
all 12 leads on the ECG. The difference between Pmax
and Pmin durations on the ECG was defined as P wave
dispersion (PWD) [21]. The laboratory tests included
complete blood count, fasting glucose level, lipid profile,
troponin level, liver, kidney, and thyroid function tests.
The weight and height of the participants were measured,
and the body mass index (BMI) (kg/m2) was calculated
using the following formula: BMI = weight/(height)2.
Echocardiographic examination and evaluation of patients

were performed using Philips Healthcare iE33 xMATRIX
Echocardiography (Philips Medical System, Andover,
MA, USA) with an S5–1 transducer before discharge.
Examinations were performed by a single experienced
cardiologist who was blinded to the patients and their
characteristics. Evaluation of the patients was performed
in the left lateral decubitus position. A continuous onelead ECG was obtained during all examinations. The
average of three consecutive beats was used to calculate the
associated parameters. M-mode echocardiography was
used in the parasternal long-axis view to measure basic
echocardiographic parameters, such as the left atrium
(LA), left ventricular (LV) end-systolic and end-diastolic
dimensions, LV ejection fraction (EF), and diastolic LV
septal and posterior wall thickness.
Electromechanical properties of the atria were
determined by tissue Doppler imaging. Before the study,
the Nyquist limit was adjusted to 15–20 cm/s and the
monitor sweep speed was set at 50–100 mm/s to optimize
the spectral display myocardial velocities. The pulsed
doppler sample volume was placed at the LV lateral and
septal mitral annulus, and subsequently at the septal mitral
annulus and right ventricular tricuspid annulus in apical
four chamber view. Atrial electromechanical delay (EMD)
was considered as the time interval from the onset of P wave
on ECG to the beginning of “A”-wave in tissue Doppler
(PA). PA interval, which was measured from the lateral
mitral, septal mitral, and tricuspid annulus was called
PA lateral, PA septum, and PA tricuspid, respectively. PA
intervals between the lateral and right ventricular annulus
were accepted as interatrial EMD, the difference between
the septal and tricuspid PA intervals as right intraatrial
EMD, and the difference between the lateral and septal PA
intervals as left intraatrial EMD.
The data were analyzed using SPSS 18.0 statistics
package (SPSS Inc., Chicago, IL, USA). Normally
distributed continuous variables were expressed as means
± standard deviation, while continuous variables with
a nonnormal distribution were expressed as median
and interquartile ranges (IQR). Student’s t-test or the
Mann–Whitney U test were used to compare the means
or medians of groups, respectively. Categorical data were
expressed as proportions and compared using the chisquare test. The relationship between antiplatelet types and
P wave duration, PWD, PR interval, P wave axis, and EMD
values was assessed by ANCOVA analysis by removing the
effects of confounding factors that were significant in the
antiplatelet and ACS types. P-values less than 0.05 were
considered statistically significant.
3. Results
A total of 1036 patients were assessed with a diagnosis
of ACS. Eighty-eight patients were excluded because of
the atrial infarction criteria and 45 patients due to the
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history of AF. After exclusion of the patients with renal
dysfunction (creatinine >1.5 mg/dL), severe valvular
heart disease, permanent pacemaker, cerebrovascular
disease, and the need for mechanical ventilation, 831
patients remained for further analysis. STEMI was found
in 486 (58.5%) and NSTEMI in 345 (41.5%) patients.
All patients were divided into two groups according to
receiving ticagrelor (410, 49.3%) or clopidogrel (421,

50.6%). The rate of patients diagnosed with STEMI in
the ticagrelor group was found to be higher than in the
clopidogrel group (72.2% versus 45.2%, P < 0.001). Table
1 summarizes the patients’ baseline characteristics. The
groups had no significant differences in terms of age, sex,
BMI, heart rate, blood pressure, creatinine, alanine amino
transferase, hemoglobin, thyroid-stimulating hormone
levels, LA diameter, and LVEF. As shown in Table 1, LDL,

Table 1. Baseline characteristics of the patients.
Total
n = 831

Ticagrelor
n = 410

Clopidogrel
n = 421

P

Age (years), mean ± SD

61.79 ± 11.97

61.04 ± 11.26

62.51 ± 12.59

0.076

Female, n (%)

223 (26.8)

103 (25.1)

120 (28.5)

0.271

Diabetes mellitus, n (%)

247 (29.7)

114 (27.8)

133 (31.6)

0.232

Hypertension, n (%)

420 (50.5)

199 (48.5)

221 (52.1)

0.254

Smoking, n (%)

420 (50.5)

220 (53.7)

200 (47.5)

0.076

Previous history of CAD, n (%)

273 (32.9)

123 (30.0)

150 (35.6)

0.084

NSTEMI

345 (41.5)

114 (27.8)

231 (54.9)

<0.001

STEMI

486 (58.5)

296 (72.2)

190 (45.1)

BMI (kg/m²), mean ± SD

27.75 ± 4.56

27.79 ± 4.69

27.70 ± 4.44

0.764

SBP (mmHg), mean ± SD

134.65 ± 26.17

136.3 ± 26.62

133.06 ± 25.67

0.077

DBP (mmHg), mean ± SD

79.74 ± 13.83

80.00 ± 14.15

79.48 ± 13.52

0.592

Heart rate (bpm), mean ± SD

75.6 ± 13.68

74.91 ± 13.8

76.26 ± 13.55

0.159

Glucose (mg/dL), median (IQR)

122 (100–165)

126 (102–168)

118 (99–162.75)

0.084

Hemoglobin (g/dL), mean ± SD

14.41 ± 1.80

14.5 ± 1.74

14.31 ± 1.85

0.139

Platelet (103/µL), mean ± SD

251.57 ± 75.59

253.89 ± 78.38

249.3 ± 72.78

0.382

Creatinine (mg/dL), mean ± SD

1.05 ± 0.22

1.05 ± 0.20

1.05 ± 0.24

0.857

Cholesterol (mg/dL), mean ± SD

191.22 ± 45.15

193.21 ± 44.15

189.21 ± 46.11

0.222

LDL (mg/dL), mean ± SD

128.85 ± 35.15

131.33 ± 34.39

126.37 ± 35.75

0.045

HDL (mg/dL), mean ± SD

39.45 ± 8.68

40.15 ± 8.54

38.75 ± 8.77

0.024

Triglyceride (mg/dL), median (IQR)

136 (98–195)

138 (99.25–195.75)

133 (97.5–194)

0.741

TSH (mIU/L), median (IQR)

1.23 (0.71–1.87)

1.22 (0.72–1.83)

1.24 (0.70–1.92)

0.914

Potassium (mmol/L), mean ± SD

4.1 ± 0.44

4.10 ± 0.43

4.11 ± 0.45

0.800

Calcium (mg/dL), mean ± SD

9.11 ± 0.6

9.15 ± 0.58

9.08 ± 0.61

0.083

Albumin (g/dL), mean ± SD

3.84 ± 0.5

3.87 ± 0.39

3.81 ± 0.58

0.158

Troponin (ng/mL), median (IQR)

11.59 (1.84–40.59)

14.15 (3.28–54.95)

9.61 (1.27–35.5)

0.003

LVEF (%), mean ± SD

48.8 ± 9.65

48.33 ± 8.98

49.27 ± 10.27

0.168

LVEDD (cm), mean ± SD

5.44 ± 0.37

5.44 ± 0.32

5.44 ± 0.40

0.808

Left atrium (cm), mean ± SD

3.68 ± 0.42

3.65 ± 0.38

3.70 ± 0.46

0.167

ACS type, n (%)

The data without normal distribution is presented as median (interquartile range).
ACS: acute coronary syndrome; BMI: body mass index; CAD: coronary artery disease; DBP: diastolic blood pressure; HDL: high
density lipoprotein; IQR: interquartile range; LDL: low density lipoprotein; LVEDD: left ventricular end-diastolic diameter; LVEF: left
ventricular ejection fraction; NSTEMI: non-ST elevated myocardial infarction; SBP: systolic blood pressure; SD: standard deviation;
STEMI: ST elevated myocardial infarction; TSH: thyrotropin stimulating hormone; WBC: white blood cell
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HDL, and 24th hour troponin levels were significantly
higher in the ticagrelor group.
In the analysis of total population data, there was
no statistically significant difference in PWD between
ticagrelor and clopidogrel groups (40.98 ± 12 ms
versus 40.06 ± 12 ms, P = 0.304) (Table 2). The other
electrocardiographic predictors of AF, such as PR interval
and P wave axis, also showed no significant difference (P
= 0.553 and P = 0.168, respectively). Subgroups analysis
according to ACS types also showed no significant
difference in PWD (NSTEMI: 41.16 ± 13.8 ms versus 40.76
± 13.55 ms, P = 0.799; STEMI: 40.9 ± 12.62 ms versus 39.19
± 11.18 ms, P = 0.132). Echocardiographic parameters are
shown in Table 2. Like electrocardiographic parameters,
we did not find any differences in echocardiographic
predictors. There was no statistically significant difference
in left intraatrial EMD, right intraatrial EMD, and
interatrial EMD between the groups (12.3 ± 2.73 ms versus
12.3 ± 2.73 ms, P = 0.314; 11.81 ± 1.39 ms versus 11.86 ±
1.33 ms, P = 0.693; 24.11 ± 3.06 ms versus 24.46 ± 3.23 ms,
P = 0.279). In addition, there was no statistically significant
difference in echocardiographic predictors of AF in the
subgroups according to ACS types. The mean interatrial
EMD values of ticagrelor and clopidogrel groups were
found as 24.53 ± 3.74 ms and 24.86 ± 3.33 ms in NSTEMI
(P = 0.644) and as 23.98 ± 2.82 ms versus 24.23 ± 3.16 ms
(P = 0.493) in STEMI subgroup (P = 0.493).
The relationship between antiplatelet types and P
wave duration, PWD and EMD values, was evaluated by
ANCOVA analysis by removing the effects of confounding
factors (age, body mass index, hypertension, CAD history,
troponin, QTc, left atrial diameter, deceleration time, and
left ventricular iso-volumetric relaxation time) that were
found to be significant between the antiplatelet groups
and the ACS subgroups. When the effects of confounding
factors were removed, there was no significant relationship
between antiplatelet use and AF predictors (P > 0.05).
From the date of treatment initiation, subgroup analysis
was performed in 66 (16.09%) patients with side effects
(mainly dyspnea, rarely others) related to ticagrelor. There
was no significant difference in terms of AF predictors
in patients with side effects related to ticagrelor when
compared to the group receiving clopidogrel or ticagrelor
without side effects. PWD was 38.79 ± 12.28 ms in patients
receiving ticagrelor that had side effects, while this value
was 41.44 ± 13.17 ms in patients without side effects (P
= 0.279) and 40.34 ± 13.14 ms in clopidogrel group (P =
0.657). Interatrial EMD was 24.23 ± 2.79 ms in patients
receiving ticagrelor and had side effects, while this value
was 24.18 ± 3.21 ms in patients without side effects (P
= 0.998) and 24.35 ± 3.01 ms in clopidogrel group (P =
0.990).

4. Discussion
Our study was designed to find out whether ticagrelor
could change AF predictors. We did not find a statistically
significant difference in PWD, interatrial and intraatrial
EMD durations between ticagrelor and clopidogrel groups
in patients with ACS.
In ACS patients, AF is seen at a high rate (approximately
10%) compared to the normal population, and this increase
has been associated with long-term increased morbidity
and mortality [22,23]. AF development in patients with
ACS is mostly attributed to ischemia and decreased atrial
perfusion, increased left ventricular end-diastolic pressure,
increased left atrial pressure, diastolic dysfunction, and
autonomic regulatory disturbances [24]. In addition,
recently, inflammation and neurohumoral factors have been
shown to be associated with AF development in patients
with ACS [24]. In our study, there were no significant
differences between the groups in parameters that could
affect the development of AF such as LA diameter, systolic
and diastolic functions of LV. Furthermore, patients with
atrial infarction criteria on ECG were excluded from
the study to reduce the possible confounding effects of
atrial ischemia [19]. Apart from the normal course of
ACS, there is a case report indicating that ticagrelor,
which increases plasma concentration of adenosine, may
cause AF [18]. PLATO trial and some case reports have
shown that ticagrelor causes bradyarrhythmias, such as
atrioventricular block and sinus node pause [3,25–27].
The most probable mechanism for these bradycardic
events appears to be increasing plasma concentration of
adenosine. Besides the bradycardic effects of adenosine,
it is known that intravenous adenosine administration
could cause spontaneous AF [15]. Moreover, endogenous
production of adenosine during metabolic stress
conditions has been suggested as a trigger of AF [28,29].
Although the mechanism is not clearly understood, this
phenomenon is thought to be mediated by adenosine’s
effects on shortening atrial action potential duration and
refractoriness [30]. Because adenosine has little effect on
atrial conduction velocity, the net effect of adenosine,
therefore, is to shorten the wavelength of activation, thereby
potentiating AF. This cellular electrophysiological effect
is mediated by its specific G protein-coupled adenosine
A1 receptor and this ligand activates the heterotrimeric
protein Gi/o, which then activates the inward rectifying
K+ current, IKAdo. In addition to that, adenosine has other
effects that may promote arrhythmogenesis. Adenosine
has sympathoexcitatory effects mediated through
baroreflex activation and chemoreceptor stimulation [30].
Adenosine can also hyperpolarize dormant pulmonary
vein myocytes and increase excitability, as well as trigger
pulmonary vein ectopy [31,32]. It has been shown that
ticagrelor increases plasma adenosine levels as early as
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67.46 ± 13.95

41.16 ± 13.8

156.75 ± 21.16

46.0 (35.0–61.5)

388.3 ± 41.3

418.34 ± 32.14

98.6 ± 12.26

53.65 ± 8.66

3.70 ± 0.41

1.00 ± 0.13

1.06 ± 0.16

49.02 ± 6.12

36.37 ± 5.74

24.49 ± 5.80

24.53 ± 3.74

11.88 ± 1.56

12.65 ± 3.52

Pmin (ms), mean ± SD

PWD (ms), mean ± SD

PR interval (ms), mean ± SD

P wave axis (degree), median (IQR)

QT interval (ms), mean ± SD

QTc interval (ms), mean ± SD

QRS duration (ms), mean ± SD

Ejection fraction (%), mean ± SD

Left atrium (mm), mean ± SD

Posterior wall (cm), mean ± SD

Septal wall (cm), mean ± SD

PA lateral (ms), mean ± SD

PA septal (ms), mean ± SD

PA tricuspid (ms), mean ± SD

Interatrial EMD (ms), mean ± SD

Right intraatrial EMD (ms), mean ± SD

Left intraatrial EMD (ms), mean ± SD

13.09 ± 3.24

11.77 ± 1.23

24.86 ± 3.33

23.66 ± 3.36

35.43 ± 3.59

48.51 ± 4.36

1.10 ± 0.15

1.03 ± 0.13

3.79 ± 0.46

52.47 ± 9.88

101.93 ± 18.91

421.69 ± 32.3

389.38 ± 36.81

45.0 (29.0–61.3)

164.72 ± 26.70

40.76 ± 13.55

67.46 ± 15.79

108.22 ± 16.67

0.504

0.672

0.644

0.396

0.337

0.635

0.044

0.123

0.066

0.283

0.086

0.428

0.829

0.231

0.135

0.799

0.999

0.820

12.20 ± 2.45

11.78 ± 1.34

23.98 ± 2.82

23.06 ± 4.47

34.84 ± 4.60

47.03 ± 5.35

1.09 ± 0.13

1.03 ± 0.11

3.64 ± 0.37

46.22 ± 8.22

98.9 ± 14.73

425.17 ± 32.53

391.36 ± 37.54

49.0 (36.8–63.0)

163.70 ± 23.41

40.9 ± 12.62

65.72 ± 13.54

106.62 ± 16.26

12.32 ± 2.77

11.91 ± 1.39

24.23 ± 3.16

22.51 ± 2.51

34.42 ± 2.82

46.74 ± 3.98

1.06 ± 0.14

1.01 ± 0.12

3.58 ± 0.43

45.33 ± 9.35

98.34 ± 13.69

422.73 ± 31.3

384.52 ± 33.94

49.0 (29.0–71.0)

162.57 ± 29.11

39.19 ± 11.18

66.67 ± 15.3

105.86 ± 16.2

Clopidogrel
n = 190

0.697

0.440

0.493

0.213

0.368

0.611

0.006

0.250

0.099

0.281

0.289

0.453

0.063

0.673

0.814

0.132

0.477

0.617

P

12.3 ± 2.73

11.81 ± 1.39

24.11 ± 3.06

23.39 ± 4.83

35.19 ± 4.91

47.49 ± 5.58

1.09 ± 0.14

1.02 ± 0.12

3.65 ± 0.38

48.33 ± 8.98

99.54 ± 14.1

423.33 ± 32.52

390.54 ± 38.55

48.0 (37.0–63.0)

162.10 ± 23.03

40.98 ± 12.94

66.2 ± 13.66

107.17 ± 15.79

Ticagrelor
n = 410

Total

12.59 ± 2.96

11.86 ± 1.33

24.46 ± 3.23

22.92 ± 2.89

34.78 ± 3.15

47.38 ± 4.20

1.08 ± 0.15

1.02 ± 0.13

3.70 ± 0.46

49.27 ± 10.27

100.22 ± 16.7

422.19 ± 31.78

387.06 ± 35.5

47.0 (29.0–63.5)

164.00 ± 27.40

40.06 ± 12.56

67.1 ± 15.56

107.16 ± 16.48

Clopidogrel
n = 421

0.314

0.693

0.279

0.259

0.337

0.820

0.721

0.897

0.167

0.168

0.571

0.645

0.226

0.168

0.553

0.304

0.376

0.993

P

The data without normal distribution is presented as median (interquartile range).
EMD: electromechanical delay; NSTEMI: non-ST elevated myocardial infarction; Pmax: the longest P wave duration; Pmin: the shortest P wave duration; PWD: P wave dispersion;
SD: standard deviation; STEMI: ST elevated myocardial infarction

108.62 ± 14.48

Pmax (ms), mean ± SD

Ticagrelor
n = 296

P

Ticagrelor
n = 114

Clopidogrel
n = 231

STEMI

NSTEMI

Table 2. Comparison of electrocardiographic and echocardiographic data by type of acute coronary syndrome.
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six hours after the loading dose in patients with ACS [33].
Therefore, the main point of our study was to determine
whether additional increase in adenosine, which is caused
by ticagrelor, would increase the susceptibility to AF.
It has been shown that PWD and Pmax are predictors
of AF [34]. Normal value for PWD is defined as 29 ± 9
ms in the literature, while a PWD > 40 ms leads to atrial
tachyarrhythmias [34,35]. Rosiak et al. also demonstrated
that PWD is predictive of AF in STEMI patients and that a
value of >25 ms is associated with increased risk for AF [36].
In our study, PWD was 40.98 ± 12 in the ticagrelor group
and 40.06 ± 12 in the clopidogrel group, and no statistical
difference was found between the two groups. PWD value
determined in our study is higher than the PWD values in
non-ACS patients in the literature, but the patient groups
show some differences. In particular, the high value of
PWD may explain the fact that since our patient group
included ACS patients, additional comorbidities were
common and LVEF was lower than other studies in the
literature. Thus, Ding et al. found that patients with cardiac
resynchronization therapy had high PWD values and
showed a decrease in PWD when EF was improved [37].
Besides electrocardiographic parameters, we also looked
at echocardiographic parameters, which were shown to
predict AF [38,39]. Likewise, in electrocardiographic
analysis, there was no statistical difference between the
interatrial, right and left intraatrial electro-mechanic
delays that were measured by TDI between ticagrelor and
clopidogrel groups.
Although recent investigations have shown that
dyspnea is caused by direct P2Y12-inhibitory effect on

the central nervous system, in our study patients with side
effects due to ticagrelor were also considered as subgroups
due to probably increased adenosine levels than those
without side effects [40]. However, subgroup analyses for
AF predictors showed no significant difference in patients
with or without side effects [20].
To the best of our knowledge, this is the first study
investigating the association between ticagrelor and
AF predictors. Nevertheless, the lack of follow-up in
terms of future arrhythmic episodes is among the major
limitations of our study. Reliable methods for detecting
AF could be used, such as long-term rhythm monitoring.
In addition, the lack of difference between the ticagrelor
and clopidogrel groups in terms of AF predictors may be
attributed to several causes. For example, possible atrial
structural disturbances due to ACS and having multiple
risk factors may have masked potential effects of adenosine
on AF development. There were also some differences in
frequency of ACS types and troponin levels in the two
study groups. Furthermore, the increase in adenosine
level caused by ticagrelor might not be sufficient to alter
the AF predictors we have investigated. It has also been
shown in the literature that adenosine causes AF in a dosedependent AF [14].
In conclusion, in this study, we found that there was
no significant difference in electro-echocardiographic AF
predictors such as PWD and EMD in ACS patients who
received ticagrelor or clopidogrel. In addition, there was
no difference even in patients with side effects, suggesting
that the possible increase in adenosine level did not lead to
AF susceptibility.
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